07:00 , Oct 31, 2011 |  BioCentury  |  Finance

IPOs on and off

IPOs on and off Cancer vaccine company NewLink Genetics Corp. updated IPO terms, while dermatology play Cutanea Life Sciences Inc. officially pulled its IPO, which dates to 2010. NewLink hopes to sell 5.5 million shares...
23:19 , Nov 5, 2010 |  BC Extra  |  Financial News

Cutanea sets IPO range

Cutanea Life Sciences Inc. (Malvern, Pa.) amended its IPO and hopes to sell 2.3 million shares at $6-$7 in an offering underwritten by Brean Murray and Rodman. A $6.50 price would raise $15 million and...
07:00 , Nov 1, 2010 |  BioCentury  |  Finance

IPO Watch

IPO watch Dermatology company Cutanea Life Sciences Inc. started on the road last week, with an IPO slated for this week. It hopes to sell 2.3 million shares at $6-$7 per share. At $6.50, the...
07:00 , Aug 16, 2010 |  BioCentury  |  Finance

2nd time the charm?

Dermatology company Cutanea Life Sciences Inc. , which last week filed to raise up to $15 million in an IPO, is taking its second shot at getting its rosacea candidate into Phase III. Cutanea's omiganan...
23:10 , Aug 13, 2010 |  BC Extra  |  Financial News

Cutanea files for IPO

Cutanea Life Sciences Inc. (Malvern, Pa.) filed to raise up to $15 million in an IPO underwritten by Brean Murray and Rodman. Cutanea's lead compound, omiganan ( CLS001 ), is expected to start Phase III...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

Omigard: Development discontinued

Cadence discontinued development of Omigard after the gel missed the primary endpoint of reduction of LCSIs vs. povidone iodine in the Phase III CLIRS trial to prevent infection from IV catheters (6% vs. 9%, p=0.08)....
08:00 , Jan 12, 2009 |  BioCentury  |  Finance

2009 milestones

2009 milestones Selected products with Phase III or regulatory milestones expected in 2009. (A) The long-acting release formulation of Byetta exenatide uses Medisorb drug delivery technology from Alkermes (NASDAQ:ALKS); (B) Endo (NASDAQ:ENDP) is acquiring Indevus...
08:00 , Jan 5, 2009 |  BioCentury  |  Finance

Phase III & cash constrained

Phase III & cash constrained Company 3Q08 oper loss 9/30/08 cash Years cash Lead program Active Biotech (SSE:ACTI) (A) $9.0 $28.1 0.78 Anyara in Ph III for renal cancer; laquinimod, which is partnered with Teva...
07:00 , Sep 25, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Various Type 2 diabetes; HIV/AIDS a-glucosidase An SAR study characterized a series of mono- and diketal, and mono- and diacetal derivatives...
07:00 , Sep 22, 2008 |  BC Week In Review  |  Clinical News

Omiganan: Phase III delayed

Migenix said that partner Cutanea would delay the start of Phase III testing of topical Omiganan to 2H09 from this half. Cutanea has exclusive rights to Omiganan for dermatological applications from Migenix (see BioCentury, March...